Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-09-20 00:00:00 ET · period of report 2022-09-16 · accession 0001567619-22-017633 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-20 | 2022-09-16 | ARQT | Burrows Scott L | CFO | M - OptEx | $1.68 | +5,000 | 40.3K | +14% | +$8,400 |
| D | 2022-09-20 | 2022-09-16 | ARQT | Burrows Scott L | CFO | M - OptEx | $0.00 | -5,000 | 37.3K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-16 | M | A | 5,000 | $1.68 | 40,256 | D | — | — | (F1) Includes 17,400 restricted stock units. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-09-16 | M | D | 5,000 | $0.00 | 37,277 | D | $1.68 · — to 2029-06-11 | 5,000 Common Stock | (F2) 25% of the shares subject to the option vest on the one year anniversary measured from May 22, 2019 (the "Vesting Commencement Date") and 1/48th of the shares vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. |